Inhibition of the OCTN1-mediated acetylcholine transport by quinidine and verapamil.
Pochini Lorena L, Cerbelli Maria Iolanda MI, Galluccio Michele M, Mariem Omar Ben OB et al.
The non-neuronal cholinergic system plays an important role in certain human diseases, such as cancer. The Novel Organic Cation Transporter, OCTN1, mediates the efflux of acetylcholine in the frame of this system, from both normal and tumour cells, providing a localised, non-neuronal source of acetylcholine that plays a crucial role in regulating fundamental cellular processes, including proliferation, differentiation, migration and immune responses. Therefore, inhibiting OCTN1-mediated acetylcholine release with repurposed drugs could represent a novel therapeutic approach. Data previously obtained by computational analysis identified quinidine and verapamil as strong OCTN1 binders. These drugs have been experimentally validated for their effects on acetylcholine transport using proteoliposome assays with both recombinant OCTN1 and OCTN1 extracted from the A549 cell line. This experimental system, based on a single-protein approach, is not affected by interferences, allowing us to describe a mixed-type of inhibition for both drugs, indicating that the binding sites for the substrate and the drugs do not fully overlap. Importantly, a trans-inhibition effect by the two drugs on the acetylcholine release was revealed. The experimental approach used proved advantageous in the highly reliable and rapid identification of the mechanism of inhibition by approved drugs.